BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26341317)

  • 1. Emotional memory impairments induced by AAV-mediated overexpression of human α-synuclein in dopaminergic neurons of the ventral tegmental area.
    Alvarsson A; Caudal D; Björklund A; Svenningsson P
    Behav Brain Res; 2016 Jan; 296():129-133. PubMed ID: 26341317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors.
    Hall H; Jewett M; Landeck N; Nilsson N; Schagerlöf U; Leanza G; Kirik D
    PLoS One; 2013; 8(5):e64844. PubMed ID: 23705016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons.
    Caudal D; Alvarsson A; Björklund A; Svenningsson P
    Exp Neurol; 2015 Nov; 273():243-52. PubMed ID: 26363495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
    Coune PG; Bensadoun JC; Aebischer P; Schneider BL
    J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
    Maingay M; Romero-Ramos M; Carta M; Kirik D
    Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy?
    Cinar E; Yalcin-Cakmakli G; Saka E; Ulusoy A; Yuruker S; Elibol B; Tel BC
    Exp Neurol; 2020 Aug; 330():113357. PubMed ID: 32437708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of alpha-synuclein in the development of the dopaminergic neurons in the substantia nigra and ventral tegmental area.
    Tarasova TV; Lytkina OA; Roman AY; Bachurin SO; Ustyugov AA
    Dokl Biol Sci; 2016; 466():5-7. PubMed ID: 27021360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit.
    Belloso-Iguerategui A; Zamarbide M; Merino-Galan L; Rodríguez-Chinchilla T; Gago B; Santamaria E; Fernández-Irigoyen J; Cotman CW; Prieto GA; Quiroga-Varela A; Rodríguez-Oroz MC
    Brain; 2023 Dec; 146(12):4949-4963. PubMed ID: 37403195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.
    Moloney TC; Hyland R; O'Toole D; Paucard A; Kirik D; O'Doherty A; Gorman AM; Dowd E
    CNS Neurosci Ther; 2014 Jan; 20(1):50-8. PubMed ID: 24279716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.
    Shahaduzzaman M; Nash K; Hudson C; Sharif M; Grimmig B; Lin X; Bai G; Liu H; Ugen KE; Cao C; Bickford PC
    PLoS One; 2015; 10(2):e0116841. PubMed ID: 25658425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration.
    Jimenez-Ferrer I; Jewett M; Tontanahal A; Romero-Ramos M; Swanberg M
    Neurobiol Dis; 2017 Oct; 106():279-290. PubMed ID: 28736195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
    Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of AAV-Alpha Synuclein NAC Antibody Improves Locomotor Behavior in Rats Overexpressing Alpha Synuclein.
    Chen YH; Wu KJ; Hsieh W; Harvey BK; Hoffer BJ; Wang Y; Yu SJ
    Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34205689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXO3 determines the accumulation of α-synuclein and controls the fate of dopaminergic neurons in the substantia nigra.
    Pino E; Amamoto R; Zheng L; Cacquevel M; Sarria JC; Knott GW; Schneider BL
    Hum Mol Genet; 2014 Mar; 23(6):1435-52. PubMed ID: 24158851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions.
    Stoyka LE; Arrant AE; Thrasher DR; Russell DL; Freire J; Mahoney CL; Narayanan A; Dib AG; Standaert DG; Volpicelli-Daley LA
    Neurobiol Dis; 2020 Feb; 134():104708. PubMed ID: 31837424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AAV2/DJ-mediated alpha-synuclein overexpression in the rat substantia nigra as early stage model of Parkinson's disease.
    von Hövel FF; Rumpel R; Ratzka A; Schreiner D; Grothe C
    Cell Tissue Res; 2019 Oct; 378(1):1-14. PubMed ID: 30989398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
    St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ
    J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
    He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J
    Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.